ASH 2014: Dr Ian Flinn discusses the treatment of haematological malignancies with idelalisib

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ian Flinn (Sarah Cannon Cancer Institute, Nashville, TN) discusses the selective oral inhibitor of phosphoinositide 3-kinase (PI3K) delta isoform (P110δ), idelalisib, in the management of haematological malignancies, including lymphoma and chronic lymphocytic leukaemia (CLL). Idelalisib is considered in combination with other therapies to enhance efficacy endpoints.

Year of Production:
Running Time:
Color/Sound:

2015
04:18
Color/Sound

Comments are closed.